CN111615515A - 杂环化合物、制备方法及其在医药上的应用 - Google Patents

杂环化合物、制备方法及其在医药上的应用 Download PDF

Info

Publication number
CN111615515A
CN111615515A CN201980008657.3A CN201980008657A CN111615515A CN 111615515 A CN111615515 A CN 111615515A CN 201980008657 A CN201980008657 A CN 201980008657A CN 111615515 A CN111615515 A CN 111615515A
Authority
CN
China
Prior art keywords
methanone
ethyl
pyrimidin
compound
dibromo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980008657.3A
Other languages
English (en)
Other versions
CN111615515B (zh
Inventor
吴予川
陈曦
黄少强
胡永韩
瞿林海
朱金莲
刘霄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evopoint Bioscience Co Ltd
Original Assignee
Suzhou Sinovent Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Sinovent Pharmaceuticals Co Ltd filed Critical Suzhou Sinovent Pharmaceuticals Co Ltd
Priority to CN202311394666.5A priority Critical patent/CN117586272A/zh
Priority to CN202110248844.8A priority patent/CN112979661B/zh
Publication of CN111615515A publication Critical patent/CN111615515A/zh
Application granted granted Critical
Publication of CN111615515B publication Critical patent/CN111615515B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Abstract

提供一种杂环化合物、制备方法及其在医药上的应用，特别是涉及一种预防和/或治疗高尿酸血症和痛风的杂环化合物、制备方法及其在医药上的应用。具体而言，提供一种如式(I)和/或式(II)所示的化合物或其互变异构体及其药学上可接受的盐、其制备方法及其治疗高尿酸血症和痛风的方法和用途。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201980008657.3A 2018-01-19 2019-01-18 杂环化合物、制备方法及其在医药上的应用 Active CN111615515B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202311394666.5A CN117586272A (zh) 2018-01-19 2019-01-18 杂环化合物、制备方法及其在医药上的应用
CN202110248844.8A CN112979661B (zh) 2018-01-19 2019-01-18 杂环化合物、制备方法及其在医药上的应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018073493 2018-01-19
CNPCT/CN2018/073493 2018-01-19
PCT/CN2019/072419 WO2019141259A1 (zh) 2018-01-19 2019-01-18 杂环化合物、制备方法及其在医药上的应用

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202311394666.5A Division CN117586272A (zh) 2018-01-19 2019-01-18 杂环化合物、制备方法及其在医药上的应用
CN202110248844.8A Division CN112979661B (zh) 2018-01-19 2019-01-18 杂环化合物、制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
CN111615515A true CN111615515A (zh) 2020-09-01
CN111615515B CN111615515B (zh) 2023-11-24

Family

ID=67301303

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202311394666.5A Pending CN117586272A (zh) 2018-01-19 2019-01-18 杂环化合物、制备方法及其在医药上的应用
CN202110248844.8A Active CN112979661B (zh) 2018-01-19 2019-01-18 杂环化合物、制备方法及其在医药上的应用
CN201980008657.3A Active CN111615515B (zh) 2018-01-19 2019-01-18 杂环化合物、制备方法及其在医药上的应用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN202311394666.5A Pending CN117586272A (zh) 2018-01-19 2019-01-18 杂环化合物、制备方法及其在医药上的应用
CN202110248844.8A Active CN112979661B (zh) 2018-01-19 2019-01-18 杂环化合物、制备方法及其在医药上的应用

Country Status (8)

Country Link
US (1) US11453674B2 (zh)
EP (1) EP3741759B1 (zh)
JP (1) JP7266901B2 (zh)
KR (1) KR20200112908A (zh)
CN (3) CN117586272A (zh)
AU (1) AU2019208785B2 (zh)
CA (1) CA3088932A1 (zh)
WO (1) WO2019141259A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7266901B2 (ja) 2018-01-19 2023-05-01 エボポイント、バイオサイエンシズ、カンパニー、リミテッド 複素環式化合物、調製方法及びその医薬的な応用
CN113527236B (zh) * 2021-08-20 2022-12-23 苏州弘森药业股份有限公司 一种制备盐酸胺碘酮的方法

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4400387A (en) * 1979-07-06 1983-08-23 S. A. Labaz-Sanofi N.V. Indolizine derivatives and uses in therapeutics
EP0149419A1 (en) * 1983-09-28 1985-07-24 Nippon Zoki Pharmaceutical Co. Ltd. Acylindole derivatives and pharmaceutical compositions containing them
US20050267108A1 (en) * 2001-12-13 2005-12-01 Hsing-Pang Hsieh Indole compounds
WO2006050006A2 (en) * 2004-11-01 2006-05-11 Wyeth ((1h-indazol-3-yl)methyl) phenols and (hydroxyphenyl)(1h-indazol-3-yl) methanones as ligands of the estrogen receptor
CN101932569A (zh) * 2007-11-29 2010-12-29 俄亥俄州立大学研究基金会 吲哚、其衍生物和类似物及其用途
WO2012048058A2 (en) * 2010-10-06 2012-04-12 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
CN106045898A (zh) * 2016-06-28 2016-10-26 广东东阳光药业有限公司 一种吲哚类化合物及其制备方法和用途
CN106432229A (zh) * 2015-09-10 2017-02-22 江苏新元素医药科技有限公司 一类用于治疗或预防高尿酸血症或痛风的化合物
CN108084186A (zh) * 2016-11-16 2018-05-29 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
CN108727267A (zh) * 2017-05-26 2018-11-02 江苏新元素医药科技有限公司 一类urat1抑制剂及其应用
CN112979661B (zh) * 2018-01-19 2022-05-17 苏州信诺维医药科技股份有限公司 杂环化合物、制备方法及其在医药上的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2502622A1 (fr) * 1981-03-25 1982-10-01 Synthelabo Derives d'imidazo (1,2-a) pyrimidines, leur preparation et leur application en therapeutique
US7636795B2 (en) 2004-06-30 2009-12-22 Intel Corporation Configurable feature selection mechanism
TWI613203B (zh) 2008-03-31 2018-02-01 Ｃ＆Ｃ新藥研究所 雜環衍生物
TWI396689B (zh) * 2008-11-14 2013-05-21 Amgen Inc 作為磷酸二酯酶１０抑制劑之吡衍生物
WO2013112878A1 (en) * 2012-01-26 2013-08-01 The Penn State Research Foundation Mcl-1 modulating compositions
CN102718735B (zh) 2012-05-28 2014-04-23 沈阳药科大学 2-乙基-3-（4-羟基）苯甲酰基苯并呋喃类化合物、组合物及其制备方法
JP6672528B2 (ja) * 2016-09-05 2020-03-25 呈和科技股▲ふん▼有限公司Ｇｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．，Ｌｔｄ． ソルビトールトリアセタールおよびモノアセタールを含む透明核剤組成物
WO2018090921A1 (zh) * 2016-11-16 2018-05-24 江苏新元素医药科技有限公司 Urat1抑制剂及其应用

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4400387A (en) * 1979-07-06 1983-08-23 S. A. Labaz-Sanofi N.V. Indolizine derivatives and uses in therapeutics
EP0149419A1 (en) * 1983-09-28 1985-07-24 Nippon Zoki Pharmaceutical Co. Ltd. Acylindole derivatives and pharmaceutical compositions containing them
US20050267108A1 (en) * 2001-12-13 2005-12-01 Hsing-Pang Hsieh Indole compounds
WO2006050006A2 (en) * 2004-11-01 2006-05-11 Wyeth ((1h-indazol-3-yl)methyl) phenols and (hydroxyphenyl)(1h-indazol-3-yl) methanones as ligands of the estrogen receptor
CN101932569A (zh) * 2007-11-29 2010-12-29 俄亥俄州立大学研究基金会 吲哚、其衍生物和类似物及其用途
WO2012048058A2 (en) * 2010-10-06 2012-04-12 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
CN106432229A (zh) * 2015-09-10 2017-02-22 江苏新元素医药科技有限公司 一类用于治疗或预防高尿酸血症或痛风的化合物
CN106045898A (zh) * 2016-06-28 2016-10-26 广东东阳光药业有限公司 一种吲哚类化合物及其制备方法和用途
CN108084186A (zh) * 2016-11-16 2018-05-29 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
CN108727267A (zh) * 2017-05-26 2018-11-02 江苏新元素医药科技有限公司 一类urat1抑制剂及其应用
CN112979661B (zh) * 2018-01-19 2022-05-17 苏州信诺维医药科技股份有限公司 杂环化合物、制备方法及其在医药上的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY 26 January 2007 (2007-01-26), retrieved from STN Database accession no. 9181173-6 *
M. F. WEMPE ET AL: "Human Uric Acid Transporter 1 (hURAT1): An Inhibitor Structure-Activity Relationship (SAR) Study", NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS, vol. 30, no. 12, pages 1525 - 7770 *

Also Published As

Publication number Publication date
KR20200112908A (ko) 2020-10-05
CA3088932A1 (en) 2019-07-25
EP3741759B1 (en) 2023-08-23
CN112979661B (zh) 2022-05-17
CN117586272A (zh) 2024-02-23
CN112979661A (zh) 2021-06-18
US20200347070A1 (en) 2020-11-05
US11453674B2 (en) 2022-09-27
WO2019141259A1 (zh) 2019-07-25
JP7266901B2 (ja) 2023-05-01
CN111615515B (zh) 2023-11-24
AU2019208785A1 (en) 2020-09-03
EP3741759A1 (en) 2020-11-25
JP2021510719A (ja) 2021-04-30
EP3741759A4 (en) 2021-11-10
AU2019208785B2 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
TWI376374B (en) Novel coumarin derivatives with antitumor activity
JP4970048B2 (ja) イミダゾ［４，５−ｃ］ピリジン化合物および抗ウイルス治療の方法
AU2006304874B8 (en) Pyrimidinones as casein kinase II (CK2) modulators
KR101060539B1 (ko) Ｐｌｋ1 저해제로서의 4-페닐-티아졸-5-카르복실산 및 4-페닐-티아졸-5-카르복실산 아미드
TWI681772B (zh) 用於治療或預防高尿酸血症或痛風的化合物及其用途
NZ573793A (en) Hiv reverse transcriptase inhibitors
KR102083818B1 (ko) 항 b형 간염 바이러스 피라졸-옥사졸리디논계 화합물
AU2008253684A1 (en) Pyrimidinones as Casein kinase II (CK2) modulators
CN112979661B (zh) 杂环化合物、制备方法及其在医药上的应用
CN113387938A (zh) 一种取代嘧啶类化合物、其制备方法、中间体及应用
WO2012173448A2 (ko) 인다논 유도체, 이의 약학적으로 허용되는 염 또는 이의 광학 이성질체, 이의 제조방법 및 이를 유효성분으로 함유하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물
KR20160071384A (ko) 고혈압 및/또는 섬유증 치료용 조성물
JP5777696B2 (ja) ２’，２−ビスチアゾール非ヌクレオシド系化合物及びその調製方法、医薬組成物、及び抗肝炎ウイルス阻害剤としての用途
CN113631541A (zh) 酰胺类化合物制备方法及其在医药领域的应用
WO2020173417A1 (zh) 含丙烯酰基的核转运调节剂及其用途
US8889713B1 (en) N-substituted tetrahydroisoquinoline benzamides/benzene sulfonamides as anti-cancer agents
US20210340147A1 (en) 2,6-DIMETHYL-N-((PYRIDlN-4-YL)METHYL)IMIDAZO[1,2-B]PYRIDAZIN-8-AMINE AND 2,5-DIMETHYL-N-[(PYRIDlN-4-YL)METHYL]PYRAZOLO[1,5-A]PYRIMIDlN-7-AMINE DERIVATIVES FOR TREATING VIRAL INFECTIONS
WO2004089939A1 (en) Condensed furan derivatives as adenosine antagonists
WO2022166990A1 (zh) 用于抗肿瘤的药物组合
RU2798107C2 (ru) Производные 2,6-диметил-n-((пиридин-4-ил)метил)имидазо[1,2-b]пиридазин-8-амина и 2,5-диметил-n-[(пиридин-4-ил)метил]пиразоло[1,5-a]пиримидин-7-амина для лечения вирусных инфекций
CN101538267A (zh) 咪唑并[4,5-c]吡啶化合物和抗病毒治疗的方法
CN116670118A (zh) 二氯苯酚hsd17b13抑制剂及其用途
JP2002322161A (ja) ビスヘテロ五員環化合物
CN103059042A (zh) 噻吩类衍生物及其在药学中的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: 215028 unit 511, building B2, 218 Xing Hu Street, Suzhou Industrial Park, Suzhou, Jiangsu.

Applicant after: Suzhou Sinoway Pharmaceutical Technology Co.,Ltd.

Address before: Unit 511, B2 / F, 218 Xinghu street, Suzhou Industrial Park, Suzhou, Jiangsu, China 215028

Applicant before: SUZHOU SINOVENT PHARMA Co.,Ltd.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant